Cargando…

On standardized relative survival

Cancer survival comparisons between cohorts are often assessed by estimates of relative or net survival. These measure the difference in mortality between those diagnosed with the disease and the general population. For such comparisons methods are needed to standardize cohort structure (including a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasieni, Peter, Brentnall, Adam R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507182/
https://www.ncbi.nlm.nih.gov/pubmed/27554303
http://dx.doi.org/10.1111/biom.12578
Descripción
Sumario:Cancer survival comparisons between cohorts are often assessed by estimates of relative or net survival. These measure the difference in mortality between those diagnosed with the disease and the general population. For such comparisons methods are needed to standardize cohort structure (including age at diagnosis) and all‐cause mortality rates in the general population. Standardized non‐parametric relative survival measures are evaluated by determining how well they (i) ensure the correct rank ordering, (ii) allow for differences in covariate distributions, and (iii) possess robustness and maximal estimation precision. Two relative survival families that subsume the Ederer‐I, Ederer‐II, and Pohar‐Perme statistics are assessed. The aforementioned statistics do not meet our criteria, and are not invariant under a change of covariate distribution. Existing methods for standardization of these statistics are either not invariant to changes in the general population mortality or are not robust. Standardized statistics and estimators are developed to address the deficiencies. They use a reference distribution for covariates such as age, and a reference population mortality survival distribution that is recommended to approach zero with increasing age as fast as the cohort with the worst life expectancy. Estimators are compared using a breast‐cancer survival example and computer simulation. The proposals are invariant and robust, and out‐perform current methods to standardize the Ederer‐II and Pohar‐Perme estimators in simulations, particularly for extended follow‐up.